source
- Paragon Therapeutics moves migraine-focused Mentari Therapeutics public via reverse mergerParagon Therapeutics, a hub-and-spoke biotech company, is taking its migraine drug subsidiary Mentari Therapeutics public through a reverse merger. The approach follows Paragon's prior use of reve…
- TrumpRx expands catalog with over 600 additional generic drugsThe White House announced that the TrumpRx direct‑to‑consumer platform has added a large batch of new generic medicines. The expansion brings the total number of generics available on the site to w…